KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Merck (MRK) Long-Term Debt Issuances (2016 - 2025)

Merck has reported Long-Term Debt Issuances over the past 11 years, most recently at $7.9 billion for Q4 2025.

Quarterly Long-Term Debt Issuances changed N/A to $7.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.9 billion through Dec 2025, up 173587.5% year-over-year, with the annual reading at $13.9 billion for FY2025, 285.66% up from the prior year.
Long-Term Debt Issuances was $7.9 billion for Q4 2025 at Merck, up from $6.0 billion in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $7.9 billion in Q4 2021 and troughed at -$7.0 million in Q3 2023.
The 4-year median for Long-Term Debt Issuances is $6.0 billion (2025), against an average of $4.4 billion.
Year-over-year, Long-Term Debt Issuances surged 85.71% in 2024 and then soared 596300.0% in 2025.
A 4-year view of Long-Term Debt Issuances shows it stood at $7.9 billion in 2021, then crashed by 100.09% to -$7.0 million in 2023, then soared by 85.71% to -$1.0 million in 2024, then soared by 791900.0% to $7.9 billion in 2025.
Per Business Quant, the three most recent readings for MRK's Long-Term Debt Issuances are $7.9 billion (Q4 2025), $6.0 billion (Q3 2025), and -$1.0 million (Q3 2024).